June 11,RegeneronAndSanofiJointly announced,FDAApproved IL-6R Monoclonal AntibodyKevzara(Sarilumab) is used to treat patients with active polyarticular juvenile idiopathic arthritis (pJIA) who weigh 63 kg or more. pJIA is a form of arthritis that affects multiple joints at once.
"For children, polyarticular juvenile idiopathic arthritis can be a painful disease as multiple joints are affected by this chronic condition,"RegeneronCo-Chairman of the Board, President and Chief Scientific OfficerGeorge D. Yancopoulos"Their daily lives are not only affected, but their futures will also be disrupted without proper treatment. The approval of Kevzara for polyarticular juvenile idiopathic arthritis offers these vulnerable patients and their families a new FDA-approved treatment option to help manage this condition."Patients with pJIA may experience joint symptoms such as pain, stiffness, and swelling, which can limit their activities and make certain aspects of their daily lives very challenging. Due to chronic joint inflammation, this condition increases the risk of permanent joint damage and growth retardation.Compared with the rheumatoid arthritis population, no new adverse reactions or safety issues were found in the pJIA population. The most common drug adverse reactions occurring in pJIA patients were nasopharyngitis, neutropenia, upper respiratory tract infection, and injection site erythema. The most common adverse reaction leading to permanent discontinuation of Kevzara treatment was neutropenia. Overall, patients receiving Kevzara had an increased risk of serious infections, which could lead to hospitalization or death.Executive Vice President and Head of Specialty Care at SanofiBrian Foard"The latest approval of Kevzara brings a new treatment option with recognized efficacy and safety for pediatric patients with polyarticular juvenile idiopathic arthritis."Copyright © 2024 PHARMCUBE. All Rights Reserved.
Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position;For reprint, please leave a message to the WeChat Official Account's backend or send a message, and indicate the name and ID of the official account.
Disclaimer: The information in this WeChat article is for general reference only and cannot be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.
